Bristol-Myers K.K.
Otsuka Pharmaceutical Co., Ltd.

June 16, 2011

Anti-cancer agent "Sprycel® 20mg Tablets and Sprycel® 50mg Tablets (dasatinib)" approved as the first-line treatment of chronic myeloid leukemia
-A new treatment option for newly-diagnosed CML patients-

Bristol-Myers K.K. (Head Office: Shijuku-ku, Tokyo; President & CEO: Emmanuel Blin) and Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President: Taro Iwamoto) today announced that they received the regulatory approval for the anti-cancer agent Sprycel as the first-line treatment of chronic myeloid leukemia (CML) on June 16, 2011. The new indication also allows the once-daily dose of up to 140mg on chronic-phase CML patients according to their conditions, an increase from the previous once-daily dose of 100mg in oral administration.